Aurobindo Pharma receives USFDA approvals for two drugs

Aurobindo Pharma Limited has received US Food &Drug Administration (USFDA) approval to make and market heartburn relief medicine Famotidine tablets of strengths 10 mg and 20 mg and Oxymorphone Hydrochloride Tablets of strengths 5 mg and 10 mg . The estimated market size for Famotidine for the 12 month period ending February 2016 was US$ 31 million whereas for Oxymorphone Hydrochloride Tablets, it is US$ 55.5 million for the same period as per data by IMS.


April 28, 2016: Aurobindo Pharma would be launching the drugs in the second quarter of FY2016-17. Aurobindo has received approvals for 257 Abbreviated New Drug Applications (ANDA) from USFDA.


* Indicates mandatory field.
Please wait while comments are being sent...